Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

LDN-212854

Copy Product Info
😃Good
Catalog No. T1900Cas No. 1432597-26-6
Alias LDN212854, BMP Inhibitor III

LDN-212854 (BMP Inhibitor III), a novel BMP inhibitor, exhibits greater selectivity for BMP versus the TGF-β type I receptors; possesses differences towards ALK2(IC50=1.3 nM) versus ALK1/3 compared to other inhibitors.

LDN-212854

LDN-212854

Copy Product Info
😃Good
Purity: 98.71%
Catalog No. T1900Alias LDN212854, BMP Inhibitor IIICas No. 1432597-26-6
LDN-212854 (BMP Inhibitor III), a novel BMP inhibitor, exhibits greater selectivity for BMP versus the TGF-β type I receptors; possesses differences towards ALK2(IC50=1.3 nM) versus ALK1/3 compared to other inhibitors.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$42In StockIn Stock
2 mg$59In StockIn Stock
5 mg$98In StockIn Stock
10 mg$185In StockIn Stock
25 mg$326In StockIn Stock
50 mg$488In StockIn Stock
100 mg$733In StockIn Stock
200 mg$1,050-In Stock
1 mL x 10 mM (in DMSO)$109In StockIn Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:98.71%
Color:White
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
LDN-212854 (BMP Inhibitor III), a novel BMP inhibitor, exhibits greater selectivity for BMP versus the TGF-β type I receptors; possesses differences towards ALK2(IC50=1.3 nM) versus ALK1/3 compared to other inhibitors.
Targets&IC50
ALK2:1.3 nM, ALK4:2133 nM, ALK5:9276 nM, ALK1:2.4 nM, BMPR1A:85.8 nM
In vitro
LDN-212854 (6 mg/kg, i.p.) effectively inactivates ALK2 signaling in vivo and efficiently inhibits ectopic ossification in inducible transgenic ALK2 mice mutants with progressive ankylosis.
In vivo
In C2C12 myoblasts, LDN-212854 demonstrates a higher selectivity for BMP6 over BMP4 in inducing osteogenic differentiation, compared to the osteogenic differentiation induced by BMP6 and BMP4.
SynonymsLDN212854, BMP Inhibitor III
Chemical Properties
Molecular Weight406.48
FormulaC25H22N6
Cas No.1432597-26-6
SmilesC1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12
Relative Density.1.33 g/cm3 (Predicted)
Storage & Solubility Information
StorageIn solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 10.42 mg/mL (25.63 mM), Sonication is recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM2.4601 mL12.3007 mL24.6015 mL123.0073 mL
5 mM0.4920 mL2.4601 mL4.9203 mL24.6015 mL
10 mM0.2460 mL1.2301 mL2.4601 mL12.3007 mL
20 mM0.1230 mL0.6150 mL1.2301 mL6.1504 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy LDN-212854 | purchase LDN-212854 | LDN-212854 cost | order LDN-212854 | LDN-212854 chemical structure | LDN-212854 in vivo | LDN-212854 in vitro | LDN-212854 formula | LDN-212854 molecular weight